Literature DB >> 12556668

Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease.

Elijah Saunders1, James R Gavin.   

Abstract

There is overwhelming evidence that the renin-angiotensin system plays a significant role in the pathophysiology of hypertension and target organ damage. Agents that regulate the renin-angiotensin system, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and aldosterone antagonists, are not only effective antihypertensive agents but can prevent target organ damage. Although diuretics remain the agents of first choice for the treatment of hypertension in African Americans, ACE inhibitors have a clear role in the management of these patients. ACE inhibitors (usually when used with a diuretic) have been shown to reduce morbidity and mortality in a wide range of patient groups. ACE inhibitors are infrequently used in African Americans because of a belief that these agents are ineffective in this racial group; however, when adequate dosing and appropriate combinations are used, ACE inhibitor therapy provides effective blood pressure control. In particular, the addition of diuretics to ACE inhibitor therapy ameliorates the racial differences in efficacy seen when ACE inhibitors are administered as monotherapy. Although further confirmation in additional clinical trials is required, increased use of these agents in African Americans will likely result in a reduction in target organ damage. Copyright 2003 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556668      PMCID: PMC8101843          DOI: 10.1111/j.1524-6175.2003.02181.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  41 in total

1.  Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity.

Authors:  M Alexander; K Grumbach; L Remy; R Rowell; B M Massie
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

2.  Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

Authors:  P Svensson; U de Faire; P Sleight; S Yusuf; J Ostergren
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Examination of racial differences in management of cardiovascular disease.

Authors:  J A Ferguson; W M Tierney; G R Westmoreland; L A Mamlin; D S Segar; G J Eckert; X H Zhou; D K Martin; M Weinberger
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

Review 4.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

Authors:  E M Lonn; S Yusuf; P Jha; T J Montague; K K Teo; C R Benedict; B Pitt
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

5.  Responses to captopril and hydrochlorothiazide in black patients with hypertension.

Authors:  M Moser; J Lunn
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

6.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

Authors:  R S McKelvie; S Yusuf; D Pericak; A Avezum; R J Burns; J Probstfield; R T Tsuyuki; M White; J Rouleau; R Latini; A Maggioni; J Young; J Pogue
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

Review 7.  Angiotensin II and the pathophysiology of cardiovascular remodeling.

Authors:  B Williams
Journal:  Am J Cardiol       Date:  2001-04-19       Impact factor: 2.778

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Racial differences in the outcome of left ventricular dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; H A Cooper; P E Carson; M J Domanski
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

10.  Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; B M Massie; E D Freis; M S Kochar; R J Hamburger; C Fye; R Lakshman; J Gottdiener
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

View more
  7 in total

1.  Elevated peripheral blood mononuclear cell-derived superoxide production in healthy young black men.

Authors:  Shekhar H Deo; Seth W Holwerda; David M Keller; Paul J Fadel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-19       Impact factor: 4.733

Review 2.  Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.

Authors:  Emil Thattassery; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

3.  Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Authors:  Mai Mehanna; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-21       Impact factor: 3.738

4.  Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.

Authors:  Whitney Wharton; Felicia C Goldstein; Malú G Tansey; Alexandra L Brown; Sonum D Tharwani; Danielle D Verble; Amarallys Cintron; Patrick G Kehoe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.

Authors:  Mai Mehanna; Zhiying Wang; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Kent R Bailey; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  Am J Hypertens       Date:  2019-06-11       Impact factor: 3.080

6.  Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.

Authors:  Steven G Chrysant
Journal:  Drugs R D       Date:  2012-06-01

7.  A novel angiotensin II peptide vaccine without an adjuvant in mice.

Authors:  Ryo Nakamaru; Hironori Nakagami; Hiroki Hayashi; Jiao Sun; Akiko Tenma; Koichi Yamamoto; Munehisa Shimamura; Ryuichi Morishita; Hiromi Rakugi
Journal:  J Hypertens       Date:  2021-01       Impact factor: 4.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.